The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation

Nephrology Dialysis Transplantation

Volumn 26, Issue 7, 2011, Pages 2394-2400

  Genberg, Helena ^a,b   Kumlien, Gunilla ^a,b   Wennberg, Lars ^a,b   Tyden, Gunnar ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

ABO incompatible; antibody rebound; antigen specific immunoadsorption; Glycosorb ABO; rituximab

Indexed keywords

BLOOD GROUP A ANTIBODY; BLOOD GROUP B ANTIBODY; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

ADULT; ANTIBODY RESPONSE; ANTIGEN SPECIFIC IMMUNOADSORPTION; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CHILD; CLINICAL ARTICLE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BLOOD GROUP ANTIGENS; BLOOD GROUP INCOMPATIBILITY; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HEMAGGLUTINATION TESTS; HUMANS; IMMUNOSORBENTS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79959919349     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr237     Document Type: Article

References (36)

1. Davis CL, Delmonico FL. Living-donor kidney transplantation: a review of the current practices for the live donor. J Am Soc Nephrol 2005; 16: 2098-2110. (Pubitemid 41716441)
2. Sonnenday CJ, Warren DS, Cooper M et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315-1322. (Pubitemid 39013579)
3. Tyden G, Kumlien G, Genberg H et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145-148. (Pubitemid 40095139)
4. Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003; 76: 730-731. (Pubitemid 37072012)
5. Gloor JM, Lager DJ, Moore SB et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003; 75: 971-977. (Pubitemid 36438524)
6. Gloor JM, Cosio FG, Rea DJ et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841-1847. (Pubitemid 44024955)
7. Montgomery RA, Locke JE, King KE et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87: 1246-1255.
8. Tanabe K, Ishida H, Shimizu T et al. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib Nephrol 2009; 162: 61-74.
9. Kayler LK, Farber JL, Colombe B et al. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation. Transpl Int 2006; 19: 128-139.
10. Dau PC. Immunologic rebound. J Clin Apher 1995; 10: 210-217. (Pubitemid 26019988)
11. Glycorex Transplantation ABLund, Sweden http://www.glycorex. com/index.php/product (26 April 2011, date last accessed).
12. Rydberg L, Bengtsson A, Samuelsson O et al. In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharose. Transpl Int 2005; 17: 666-672. (Pubitemid 40558223)
13. Rydberg L, Breimer ME, Holgersson J et al. Characterisation of the anti-A antibody response following an ABO incompatible (A2 to O) kidney transplantation. Mol Immunol 1992; 29: 547-560.
14. Rydberg L, Breimer ME, Brynger H et al. ABO-incompatible kidney transplantation (A2 to O). Qualitative and semiquantitative studies of the humoral immune response against different blood group A antigens. Transplantation 1990; 49: 954-960. (Pubitemid 20171967)
15. Breimer ME, Rydberg L, Jackson AM et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 2009; 87: 549-556.
16. Sumitran-Holgersson S, Wilczek HE, Holgersson J et al. Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002; 74: 268-277. (Pubitemid 34810296)
17. Genberg H, Kumlien G,Wennberg L et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008; 85: 1745-1754.
18. Kumlien G, Wilpert J, Safwenberg J et al. Comparing the tube and gel techniques for ABO antibody titration, as performed in three European centers. Transplantation 2007; 84: S17-S19.
19. Ishida H, Koyama I, Sawada T et al. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. Transplantation 2000; 70: 681-685. (Pubitemid 30659655)
20. Squifflet JP, De Meyer M, Malaise J et al. Lessons learned from ABO-incompatible living donor kidney transplantation: 20 years later. Exp Clin Transplant 2004; 2: 208-213.
21. Tobian AA, Shirey RS, Montgomery RA et al. ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant 2010; 10: 1247-1253.
22. Van den Hoogen FH, Boerbooms AM, Van de Putte LB et al. Rebound of anti-topoisomerase I antibody titres after plasma exchange. Ann Rheum Dis 1993; 52: 246-247. (Pubitemid 23094323)
23. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714. (Pubitemid 36745243)
24. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723. (Pubitemid 29082898)
25. Lindblad HG, Berg UB. Comparative evaluation of iohexol and inulin clearance for glomerular filtration rate determinations. Acta Paediatr 1994; 83: 418-422. (Pubitemid 24136713)
26. Vieira CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542-548. (Pubitemid 38282809)
27. Alwayn IP, Xu Y, Basker M et al. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody. Xenotransplantation 2001; 8: 157-171. (Pubitemid 32655981)
28. Valli PV, Puga Yung G, Fehr T et al. Changes of circulating antibody levels induced by ABO antibody adsorption for ABO-incompatible kidney transplantation. Am J Transplant 2009; 9: 1072-1080.
29. Gloor JM, Lager DJ, Fidler ME et al. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005; 80: 1572-1577. (Pubitemid 43005868)
30. Genberg H, Hansson A, Wernerson A et al. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418-2428. (Pubitemid 44359429)
31. Rieben R, Korchagina EY, von Allmen E et al. In vitro evaluation of the efficacy and biocompatibility of new, synthetic ABO immunoabsorbents. Transplantation 1995; 60: 425-430.
32. Lependu J, Lambert F, Samuelsson B et al. Monoclonal-antibodies specific for type-3 and type-4 chain-based blood-group determinants- relationship to the a1 and a2 subgroups. Glycoconjugate J 1986; 3: 255-271.
33. Lindberg L, Johansson SM, Liu J et al. Is there a clinical need for a diagnostic test allowing detection of chain type-specific anti-A and anti-B. Transfusion 2010; 51: 494-503.
34. Breimer ME, Samuelsson BE. The specific distribution of glycolipidbased blood group A antigens in human kidney related to A1/A2, Lewis, and secretor status of single individuals. A possible molecular explanation for the successful transplantation of A2 kidneys into O recipients. Transplantation 1986; 42: 88-91. (Pubitemid 16058486)
35. Rydberg L, Skogsberg U, Molne J. ABO antigen expression in graft tissue: is titration against donor erythrocytes relevant?. Transplantation 2007; 84: S10-S12.
36. Rydberg L. ABO-incompatibility in solid organ transplantation. Transfus Med 2001; 11: 325-342 (Pubitemid 32771925)